Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Shareholder Meeting (April 2020)
37 slides from Zealand Pharma A/s's shareholder meeting presentation, Apr 7, 2020
Slide 1: Annual 2020 General Meeting Zealand Pharma
Annual 2020 General Meeting Zealand Pharma April 2, 2020
Slide 2: Introduction and report from the Chairman
Introductionandreport from the Chairman Martin Nicklasson Chairman of the Board 2
Slide 3: Agenda
Agenda 1. 2. 3. 4. 5. 6. 7. 8. 9. Management’s report on the Company's activities during the past financial year Approval of the audited Annual Report 2019 Resolution on the cover of loss in accordance with the approved Annual Report 2019 Election of members to the Board of Directors Election of the
Slide 4: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 5: Management report for 2019: Delivering on our commitment to patients
Management reportfor 2019: Deliveringonour commitment topatients Emmanuel Dulac President and Chief Executive Officer 5
Slide 6: Zealand Pharma Organizational Chart
Zealand Pharma Organizational Chart as of April 2, 2020 Finance & Support Business Development, International Commercial & New Product Planning Marino Garcia Senior Vice President President & Chief Executive Officer Emmanuel Dulac U.S. Commercial TBD Senior Vice President Exec. Assistant & Admin. Te
Slide 7: 2019 was a transformative year for Zealand Pharma
2019 was a transformative year for Zealand Pharma Dasiglucagon HypoPal® rescue pen: Clinical program completed and NDA submission on track for Q1 2020 Dasiglucagon for dual-hormone pump: Phase 2 completed Dasiglucagon for congenital hyperinsulinism: Second pivotal Phase 3 trial initiated Dasiglucago
Slide 8: Alexion Pharmaceuticals partnership
Alexion Pharmaceuticals partnership Complement inhibitors in pre-clinical program: development Strategic collaboration for up to four complement pathway targets Key financials Lead Target • Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to
Slide 9: Superior glycemic control with dual hormone pump using dasiglucagon
Superior glycemic control with dual hormone pump using dasiglucagon for automated management of diabetes Phase 2 home-use clinical trial testing the iLet™ Bionic Pancreas using Dasiglucagon1 9 1 Beta Bionics and Zealand Pharma joint company announcement, June 6, 2019; 2 www.betabionics.com; Beta Bio
Slide 10: NDA submitted to U.S. FDA for Dasiglucagon HypoPal Rescue Pen
NDA submitted to U.S. FDA for Dasiglucagon HypoPal® Rescue Pen to treat severe hypoglycemia Potential for fast rescue from hypoglycemia For illustration only Pivotal Phase 31 Confirmatory Phase 33 Pediatric Phase 34 40 min 35 min 30 min 10 min 10 min 10 min 12 min 10 min GlucaGen® 1.0 mg Dasiglucago
Slide 11: Multiple opportunities with dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve modalities patients’ lives with dasiglucagon via different product Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation Suitable for multiple indications HypoPal® rescue pen for severe hypoglycemia Dua
Slide 12: Two promising programs for short bowel syndrome
Advancing two promising programs to address severe unmet medical needs for patients with short bowel syndrome Glepaglutide GLP-2 analog ZP 7570 GLP-1R/GLP-2R dual agonist Pivotal Phase 3 Phase 1a • Evaluate once-and twice-weekly glepaglutide dosing over 24 weeks Patient enrollment completion expecte
Slide 13: Oral α4β7 integrin inhibitor ZP10000 via Encycle acquisition
Orally-delivered a4b7 integrin inhibitor (ZP10000) added to early pipeline through Encycle Therapeutics acquisition α4β7 integrin inhibitor: ZP100001 Encycle Therapeutics acquisition • ZP10000 inhibits integrin α4β7, which is involved in migration of circulatory pro-inflammatory lymphocytes to intes
Slide 14: Boehringer Ingelheim partnership program
Boehringer Ingelheim partnership program: Next generation peptide therapeutics for obesity / type 2 diabetes Key figures GLP-1/glucagon dual analog1 • Product candidate for obesity/ T2D €365 million2 • Once weekly dosing Outstanding potential development, regulatory and commercial milestones • Phase
Slide 15: Historical performance in 2019 outperformed comparable indices
Historical performance in 2019 outperformed comparable indices Zealand Pharma (ZEAL-CSE) Zealand Pharma (ZEAL-US) NASDAQ Biotech OMX Nordic Copenhagen Mid Cap 330 Alexion agreement ; DHAP Ph 2 Results ; Dasi RP Ph 3 Ped Results; 280 230 180 ; New CEO ; New CFO 130 18FY Report ;61472;19Q1 Report ;19H
Slide 16: Company Goals 2020
Company Goals 2020 Build Zealand Pharma U.S. and advance our launch readiness Execute on the clinical pipeline and NDA filing Advance early pipeline and Maintain a strong financial strategic alliances and organizational position 16
Slide 17: Multiple late stage programs and a promising early pipeline
Multiple late stage programs and a promising early pipeline Dasiglucagon S.C. Continuous Infusion Congenital hyperinsulinism Dasiglucagon Dual-hormone Pump Diabetes management Glepaglutide GLP-2 Analog Short bowel syndrome ZP 7570 GLP-1/GLP-2 Dual Agonist Short bowel syndrome BI 456906 GLP-1/GLU Dua
Slide 18: In 2020, U.S. infrastructure will become fully operational
In 2020, U.S. infrastructure will become fully operational while we continue advancing across our pipeline • • Establish Boston-area office for Zealand Pharma U.S. operations Execute launch readiness program for dasiglucagon HypoPal® rescue pen Build Zealand Pharma U.S. and advance launch readiness
Slide 19: Acquisition of Valeritas accelerates build of U.S. operations
Acquisition of Valeritas accelerates build of U.S. operations Zealand U.S. organization expands 10 120 employees Integrating our systems together Building a strong foundation to launch dasiglucagon HypoPal® rescue pen in 2021 19
Slide 20: Marlborough as Zealand's next location
We are excited to add Marlborough as Zealand’s next location Boston Marlborough Copenhagen New York 20
Slide 21: Our response to COVID-19
Our response to COVID-19: precautions to keep our employees, patients, and business and clinical partners safe, while sustaining business Take swift decisions on immediate risks affecting • • • • • • Employees Patients and our clinical Product supply Key Projects Market value Finances studies Plan f
Slide 22: Built on a solid foundation, Zealand has an exciting future
Built on a solid foundation, Zealand has an exciting future 1998 Year established in Denmark 179 Employees, 85% in R&D 2 Therapies in US market (2017) 4 Late stage assets and robust early pipeline 5x25 5 commercialized products by 2025 Dual NASDAQ listings in Copenhagen (2010 IPO) and NYC (2017) Off
Slide 23: Financial Highlights
FinancialHighlights Matt Dallas Chief Financial Officer 23
Slide 24: 2019 income statement
2019 income statement 24 Exchange rates used: 31 Dec 2019 = 6.6759 and 31 Dec 2018 = 6.5194 DKK ‘000 FY 2019 Restated FY 2018 Revenue (royalties and milestone payments) Royalty expenses Research and development expenses Administrative expenses Other operating income Operating result Net financial it
Slide 25: A strong financial position to support our clinical programs
A strong financial position to support our clinical programs Net Operating Expenses DKK 628.9 million / USD 94.2 million Cash position DKK 1.38 billion / USD 207 million R&D and Administrative Expenses DKKm Cash and cash equivalents, restricted cash and securities DKKm $m 105 $m 240 1.600 700 1.400
Slide 26: 2020 financial guidance
2020 financial guidance The increase in net operating expenses in 2020 compared to 2019 is due to • a rise in administrative expenses as Zealand prepares for the product launch and subsequent commercialization for the dasiglucagon HypoPal® Rescue Pen, as well as the clinical development costs associ
Slide 27: Comments & Questions
Comments & Questions 27
Slide 28: Agenda items 1, 2 & 3 – Joint Resolutions
Agenda items 1, 2 & 3 – Joint Resolutions 1. Management’s report on the Company's activities during the past financial year 2. Approval of the audited Annual Report 2019 3. Resolution on the cover of loss in accordance with the approved Annual Report 2019 28
Slide 29: Election of members to the Board of Directors
Agenda item 4 Election of members to the Board of Directors All of the incumbent board members are standing for re-election and the Board of Directors proposes, in accordance with the recommendation from the Nomination Committee, re-election of all the members: Jeffrey Berkowitz Martin Nicklasson Ki
Slide 30: Election of members to the Board of Directors
Agenda item 4 Election of members to the Board of Directors All of the incumbent board members are standing for re-election and the Board of Directors proposes, in accordance with the recommendation from the Nomination Committee, re-election of all the members: Leonard Kruimer Bernadette Connaughton
Slide 31: Election of auditor
Agenda item 5 Election of auditor As recommended by the Audit Committee, the Board of Directors proposes election of Ernst & Young Godkendt Revisionspartnerselskab as the Company's auditor 31
Slide 32: Authorization to acquire treasury shares and ADSs
Agenda item 6 Authorization to Zealand to acquire treasury shares directly and/or American Depositary Shares The Board of Directors requests that the General Meeting authorizes the Company to acquire, during the period until the next Annual General Meeting, treasury shares directly and/or acquire Am
Slide 33: Proposal to approve a new Remuneration Policy
Agenda item 7 Proposal by the Board of Directors to approve a new Remuneration Policy for the Company Compared to the Company's existing Remuneration Policy, the Board of Directors has proposed few amendments in the new Remuneration Policy, including: • New terms in regard to vesting and exercise pe
Slide 34: Proposal to approve Board of Directors fees for 2020
Agenda item 8 Proposal from the Board of Directors year 2020 to approve the fees for the Board of Directors for the financial • Member base fee of DKK 400,000 • Chairman fee of DKK 350,000 • Vice-Chairman fee of DKK 100,000 • Audit Committee member fee of DKK 50,000 • Audit Committee chairman fee of
Slide 35: Proposals to amend the Articles of Association
Agenda items 9-12 Proposal from the Board of Directors to amend the Company's Articles of Association Item 9 Replacement of Section 7.1 regarding the Board of Directors' authorization to increase the share capital of the Company Item 10 Replacement of Section 7.2 regarding the Board of Directors' au
Slide 36: Any other business
Agenda item 13 Any other business 36
Slide 37: Thank you
Thank you Zealand Pharma Annual General Meeting April 2, 2020